Skip to main content
Equibles
AVBP logo

AVBP · ArriVent BioPharma, Inc. · Metrics

Track AVBP — free

Use AVBP with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AVBP.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$18.85 +0.91 (+5.07%) At close · Oct 20
Russell 2000 member Rebalance outlook locked
Market Cap
$921.31M
Shares
49.31M
Volume · Oct 20 817.87K Avg daily vol (3M) 1M

AVBP metrics

62 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$18.85
Market cap
$921.31M

Price action

20 metrics
Price change (1W)
+9.0%
Price change (30D)
-39.7%
Price change (3M)
-36.4%
Price change (6M)
-42.8%
Price change (YTD)
-10.8%
Price change (1Y)
-8.0%
Trailing year
Price change (5Y)
—
52-week high
$34.74
52-week low
$15.09
Change from 52-week high
-48.4%
Change from 52-week low
+18.9%
Annualized volatility
74.9%
Annualized volatility (3M)
107.6%
Beta
1.0
RSI (14D)
32.3
Price vs SMA 50
-33.7%
Price vs SMA 200
-33.8%
Avg volume (3M)
1.00M
Relative volume
1.0
Average dollar volume
$22.16M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
49.31M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
2.4
reciprocal yield 42.1%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-18.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-05-11

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$175.94M
Net income (TTM)
−$163.74M
Trailing 12 months
Diluted EPS (TTM)
$-3.53
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-3.95
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-3.67
Operating cash flow per diluted share (TTM)
$-3.33
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$3.24
Stock compensation per diluted share (TTM)
$0.43
Book value per share
$7.24

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+36.0%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-44.6%
Return on assets
-41.5%
Debt / equity
0.0
Current ratio
14.2
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
14.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$373.12M
Latest balance sheet
Cash & equivalents
$154.68M
Total assets
$394.72M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$147.93M
Capital expenditures (TTM)
—
R&D (TTM)
$144.30M
SG&A (TTM)
—
Stock compensation (TTM)
$19.09M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
159
13F filer change QoQ
+19
Institutional ownership
95.5%
Conviction holders (share of 13F filers)
7.0%
Crowding (high-turnover and private-fund holders)
56.9%
Private-fund adviser ownership
54.2%
Active holders' share change QoQ
+6.8%
Holder tenure
7.8
Price vs estimated holder cost
+56.4%

Ownership (registered funds)

1 metrics
Index-fund ownership
12.4%

Short interest

3 metrics
Short interest
17.1%
Latest settlement · 11.3 days to cover
Days to cover
11.3d
Short-squeeze score
73 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1868279 CUSIP 04272N102 13F (30d) 10 filings 10 filers Visit website Investor relations